Clovis Oncology Inc (fka CLVSQ) (CLVSQ)

[bandit007]

Looking strong here

[swingingRichard]

Funny. I seem to have no regrets.

[beambe]

Volume

[liamlinden]

wow took a hit today as I bought more yesterday

[liamlinden]

we have seen the bottom.Clvs will be bought out in next 12 months with double digits .I have been buying past 2 days but I also bought at$4,65 so that hurts in the short term.

[beambe]

Bingo

[beambe]

goo 0,50 $

[beambe]

good NEWS...Two additional top-line Phase 3 data reads for Rubraca are expected over the next 12 months, with the potential to target ovarian and prostate cancer patient populations

[beambe]

4 Phase 3

[swingingRichard]

No one should ever regret taking profit. Bulls make money. Bears make money. Pigs get slaughtered.

[ShortSale4U]

Market movers are trash parasites to the stock market.

[ShortSale4U]

All who sold will regret soon !

[trendzone]

Up market, down market, its not going to matter, sooner more than later, naked shorting criminals are going to get blown up in the worse way.

[ShortSale4U]

Market movers holding this back. See some daylight in 3.10s

[beambe]

n Phase 3 is very rare-https://clovisoncology.com/pipeline/pipeline-overview/

[trendzone]

Shorts days are numbered, sometimes that could be by minutes.

[beambe]

okay

[beambe]

Volume: 71,780,927 @04/04/22 3:33:30 PM EDT

[Hercules1]

One of the most promising biotech out there.

Target price: $50

[beambe]

https://clovisoncology.com/pipeline/pipeline-overview/

[beambe]

good Volume

[Hercules1]

It will get back over $3.

Looking for a $3.50 possible close.


This is a very promising biotech.

[jchords]

Nice pop at open

[Pyramid2]

Interesting setup going into Monday, glta.

[swingingRichard]

This thing is volatile. The PPS has covered a wide range. About 5-ish years ago it ran to Ben Franklin's range.

[JoEy D BuLL]

whaat

[crudeoil24]

I made big $$$$$ in LGVN. > Alzheimer Journal

[Pyramid2]

and the sell off - the money was LGVN today, this continues to be a shorting paradise...and Master Putin is going to explode Oil & Gas April 1st.

[bcapps66]

Drove this back down today. What a shame. Only had momo in pm and the first 30 minutes of trading.

[bcapps66]

They are doing a damn fine job.....grrrrrrrrrrrrrrrrrrrrrr.

[crudeoil24]

Revenue per employee is $360K >
( MarketWatch)

CLVS

[crudeoil24]

Trading float > 139M

CLVS

[crudeoil24]

ATHENA is a double-blind, placebo-controlled, Phase 3 trial of rucaparib in first-line ovarian cancer maintenance treatment. It has two parts which are statistically independent. The top-line results reported today are from the ATHENA-MONO part (rucaparib vs placebo) with results from the ATHENA-COMBO part (rucaparib+nivolumab vs rucaparib) now expected in Q1 2023 based on a slower than expected event count.


CLVS

[crudeoil24]

MASSIVE VOLUME!

CLVS

[bcapps66]

Well I hope they don't succeed ;)

[trendzone]

Short manipulators trying everything they can to keep it from trashing them over $3.00, even do they know they will most likely end up getting squeezed over level, if not today, in the very near future.

[XenaLives]

Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

   
    Settlement Date/ Short Interest/ Percent Change/    
   Average Daily Share Volume/ Days to Cover    
    
 01/31/2022	27,952,664	4.70	 5,300,083	 5.27 
 01/14/2022	26,698,168	7.98	 3,948,669	 6.76 
 12/31/2021	24,724,467	(5.65)	 3,774,824	 6.55 
 12/15/2021	26,204,634	(1.03)	 4,279,886	 6.12 
 11/30/2021	26,478,040	0.04	 4,438,146	 5.97 
 11/15/2021	26,468,381	(0.48)	 3,349,305	 7.90 
 10/29/2021	26,596,383	4.63	 2,162,794	12.30 
 10/15/2021	25,419,099	(4.49)	 1,969,717	12.90 
 09/30/2021	26,613,247	6.34	 3,129,379	 8.50 
 09/15/2021	25,027,170	(7.89)	 3,486,045	 7.18 
 08/31/2021	27,171,207	(2.51)	 3,046,465	 8.92 
 08/13/2021	27,869,592	(5.61)	 2,743,356	10.16 
 07/30/2021	29,524,548	4.27	 2,999,480	 9.84 
 07/15/2021	28,316,566	4.11	 6,153,593	 4.60 
 06/30/2021	27,199,389	(5.05)	 5,863,372	 4.64 
 06/15/2021	28,646,533	(7.13)	11,471,583	 2.50 
 05/28/2021	30,844,974	(1.88)	 3,635,644	 8.48 
 05/14/2021	31,435,972	3.20	 4,555,836	 6.90 
 04/30/2021	30,460,876	(3.78)	 2,884,088	10.56 
 04/15/2021	31,658,900	(1.80)	 3,627,186	 8.73 
 03/31/2021	32,239,203	(6.53)	35,843,888	 1.00  
 03/15/2021	34,492,178	(4.71)	6,533,895	 5.28  
 02/26/2021	36,195,328	9.61	8,531,539	 4.24   
 02/12/2021	33,023,032	(8.49)	9,169,109	 3.60   
 01/29/2021	36,085,294	(0.08)	12,480,380	 2.89   
 01/15/2021	36,115,964	(1.58)	4,529,182	 7.97   
 12/31/2020	36,694,330	18.72	5,772,617	 6.36   
 12/15/2020	30,907,481	(8.12)	4,371,629	 7.07   
 11/30/2020	33,640,719	(14.87)	3,790,804	 8.87   
 11/13/2020	39,517,472	(2.80)	5,436,036	 7.27    
 10/30/2020	40,653,967	3.19	2,920,624	13.92    
 10/15/2020	39,395,343	0.59	3,566,878	11.04    
 09/30/2020	39,165,763	3.28	4,839,373	 8.09    
 09/15/2020	37,921,616	3.70	4,966,590	 7.64    
 08/31/2020	36,567,733	1.28	5,361,011	 6.82    
 08/14/2020	36,106,607	6.45	4,612,817	 7.83     
 07/31/2020	33,917,252	3.87	 3,254,863	10.42     
 07/15/2020	32,653,635	7.96	 3,147,715	10.37      
 06/30/2020	30,244,846	16.05	 4,440,585	 6.81      
 06/15/2020	26,061,751	(4.32)	 4,444,238	 5.86      
 05/29/2020	27,239,015	2.76	10,723,636	 2.54      
 05/15/2020	26,507,994	23.82	 8,097,608	 3.27      
 04/30/2020	21,408,484	(8.34)	 5,552,583	 3.86      
 04/15/2020	23,356,262	(7.02)	 3,908,466	 5.98      
 03/31/2020	25,118,416	(2.07)	 8,103,375	 3.10      
 03/13/2020	25,648,785	7.73	 5,206,303	 4.93      
 02/28/2020	23,809,064	(7.08)	 8,945,089	 2.66      
 02/14/2020	25,622,422	(0.08)	 5,286,567	 4.85      
 01/31/2020	25,642,035	25.93	 7,272,759	 3.53      
 01/15/2020	20,362,771	(24.28)  6,731,086	 3.03      
 12/31/2019	26,890,498	0.13	 5,435,540	 4.95      
 12/13/2019	26,855,728	(2.10)	17,911,481	 1.50      
 11/29/2019	27,431,603	1.85	16,550,496	 1.66      
 11/15/2019	26,932,138	22.53	12,804,991	 2.10      
 10/31/2019	21,979,837	2.21	 3,916,605	 5.61      
 10/15/2019	21,503,874	3.58	 3,126,971	 6.88      
 09/30/2019	20,761,101	(6.58)	 4,819,292	 4.31      
 09/13/2019	22,223,363	6.11	 3,109,896	 7.15      
 08/30/2019	20,943,066	19.86	 3,063,310	 6.84      
 08/15/2019	17,473,086	82.03	 6,821,417	 2.56      
 07/31/2019	9,599,270	(14.21)	 2,124,097	 4.52      
 07/15/2019	11,189,700	7.35	 1,579,277	 7.0   
     

[XenaLives]

Clovis Oncology Inc. [CLVS] Revenue clocked in at $156.10 million, down -24.35% YTD: What’s Next?
By Caleb Clifford -February 10, 2022
Clovis Oncology Inc. [NASDAQ: CLVS] jumped around 0.16 points on Wednesday, while shares priced at $2.05 at the close of the session, up 8.47%. The company report on January 10, 2022 that Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021.

Estimated $35.5M – $36.1M in Rubraca® (rucaparib) global sales for Q4 2021 and $148.3M – $148.9M for FY 2021.

Continuing impact on ovarian cancer diagnoses and treatments from COVID-19.

Clovis Oncology Inc. stock is now -24.35% down from its year-to-date (YTD) trading value. CLVS Stock saw the intraday high of $2.09 and lowest of $1.91 per share. The company’s 52-week high price is 10.74, which means current price is +19.88% above from all time high which was touched on 01/03/22.

Compared to the average trading volume of 4.30M shares, CLVS reached a trading volume of 7530240 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Clovis Oncology Inc. [CLVS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLVS shares is $5.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLVS stock is a recommendation set at 3.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Clovis Oncology Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 18, 2020. The new note on the price target was released on April 27, 2020, representing the official price target for Clovis Oncology Inc. stock. Previously, the target price had yet another raise to $6, while BofA/Merrill analysts kept a Underperform rating on CLVS stock. On January 08, 2020, analysts decreased their price target for CLVS shares from 36 to 27.

The Average True Range (ATR) for Clovis Oncology Inc. is set at 0.20, with the Price to Sales ratio for CLVS stock in the period of the last 12 months amounting to 1.66.

How has CLVS stock performed recently?
Clovis Oncology Inc. [CLVS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.04. With this latest performance, CLVS shares dropped by -20.85% in over the last four-week period, additionally sinking by -57.38% over the last 6 months – not to mention a drop of -78.51% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLVS stock in for the last two-week period is set at 43.50, with the RSI for the last a single of trading hit 48.42, and the three-weeks RSI is set at 41.48 for Clovis Oncology Inc. [CLVS]. The present Moving Average for the last 50 days of trading for this stock 2.5900, while it was recorded at 1.8800 for the last single week of trading, and 4.3100 for the last 200 days.

Clovis Oncology Inc. [CLVS]: Deeper insight into the fundamentals
Clovis Oncology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.90 and a Current Ratio set at 2.00.

https://dbtnews.com/2022/02/10/clovis-oncology-inc-clvs-revenue-clocked-in-at-156-10-million-down-24-35-ytd-whats-next/

[swingingRichard]

Doesn't LOOK like a short squeeze.

[makinezmoney]

$CLVS: I hear ONCOLOGY plays are HOT again


AFter that buyout by Pfizer this week of Trillium Therapeutics.


https://www.thestreet.com/investing/pfizer-agrees-2-26-billion-takeover-of-trillium-therapeutics


Chart looks favorable here on $CLVS at $4.50

Could easily double from here



GO $CLVS

[swingingRichard]

That article is so idiotic it’s not even wrong. The base assumption is incorrect and without a good foundation the argument just falls apart and sounds silly.

[BRONSON]

This is BS my 515 should be 6 bucks by now daddy needs a new pair of shoes when are you guys gonna realize that's it bottoms up time to cover? What do you wanna do 7 or 8 ?...
That's what's gonna happen if everybody does it at once.

[AlphaStockNews]

$CLVS a short squeeze is coming. Hold onto your hats, it's going to be a wild ride! https://cnafinance.com/clovis-oncology-clvs-stock-is-gearing-up-for-a-short-squeeze/

[Strider212]

CLVS Making good things happen!

https://www.businesswire.com/news/home/20210628005051/en/

[luvbio]

Trading is acting better, but it's got a ways to go, before I get excited. It's been in a fairly tight trading range, for quite awhile.

[swingingRichard]

nah. entry point was < $5.50.

[Song time]

Great entry point

[luvbio]

Wow, look at that volume - is that the reddit crowd?

[Strider212]

Holding very well against the shorts at the $6 range. This, along with the huge volume already today is just another strong indicator of the squeeze coming on!!! Go $CLVS!!!

[ClayTrader]

* * $CLVS Video Chart 06-09-2021 * *

Link to Video - click here to watch the technical chart video